Treatment Patterns and Clinical Outcomes of Patients With Resectable Non–Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy: A Large-Scale, Multicenter, Real-World Study (NeoR-World)

This article evaluates the effectiveness of neoadjuvant immunotherapy combined with chemotherapy (IC+Chemo) in treating non-small cell lung cancer (NSCLC). This large-scale study involved 1,092 patients from 11 medical centers and compared outcomes between those who received IC+Chemo and those who received chemotherapy alone. Key findings show significantly better outcomes for the IC+Chemo group, with higher rates of pathologic complete response (32.8 percent) and disease-free survival (82 percent) at two years. Patients with squamous cell carcinoma benefited the most from the combined treatment. Additionally, adjuvant therapy following surgery was identified as a critical factor in improving long-term survival, particularly in patients with lower pathologic responses.  This study validates the superiority of neoadjuvant immunochemotherapy in improving survival outcomes for NSCLC, helping surgeons and oncologists in refining treatment strategies for better patient care​.